SCHEMBL4456749

SCHEMBL4456749

c1ccc(OCc2nc(-c3ccc(Oc4ccncc4)cc3)c[nH]2)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 1/20 0.43
LTA4H P09960 4/20 0.43
MCL1 Q07820 1/20 0.42
CYP11B1 P15538 1/20 0.41
CYP11B2 P19099 1/20 0.41
RAB9A P51151 5/20 0.40
XDH P47989 2/20 0.40
NPC1 O15118 3/20 0.40
TP53 P04637 1/20 0.39
TSHR P16473 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
MAPK13 O15264 1/20 0.39
GCGR P47871 1/20 0.39
MAPK12 P53778 1/20 0.39
MAPK11 Q15759 1/20 0.39
MAPK14 Q16539 1/20 0.39
RIPK1 Q13546 1/20 0.38
SCN4A P35499 1/20 0.38
TNK2 Q07912 1/20 0.37
GSK3B P49841 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4686964 0.93 MCL1 (0.46) LTA4HMCL1CYP11B1CYP11B2RAB9A
SCHEMBL4456543 0.88 MCL1 (0.54) PRMT5MCL1RAB9AXDHNPC1
SCHEMBL4460360 0.88 LTA4H (0.47) LTA4HMCL1RAB9AXDHNPC1
SCHEMBL3270671 0.87 MAOA (0.46) LTA4HMCL1RAB9AXDHNPC1
SCHEMBL4680696 0.87 MCL1 (0.48) LTA4HMCL1RAB9AXDHNPC1
SCHEMBL4455245 0.87 NPC1 (0.50) LTA4HMCL1RAB9AXDHNPC1
SCHEMBL4460188 0.87 NPC1 (0.45) LTA4HMCL1RAB9AXDHNPC1
Hydrochloric Acid SCHEMBL4461345 0.86 XDH (0.45) LTA4HMCL1RAB9AXDHNPC1
SCHEMBL4465047 0.86 PRMT5 (0.42) PRMT5RAB9ANPC1TP53TSHR
SCHEMBL4680834 0.85 MAOB (0.47) LTA4HMCL1RAB9AXDHNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7534805-B2 Imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) 2009-05-19 US disclosed
EP-1638943-B1 NOVEL IMIDAZOLE DERIVATIVES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS A MEDICAMENT SOD CONSEILS RECH APPLIC (FR) 2008-08-06 EP disclosed
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATION SCIENTIFIQUES (S.C.R.A.S.) (FR) 2007-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070066542-A1 Novel imidazole derivatives, their preparation and their use as medicaments MIF, MCL1, PPIP5K2 PRMT5 442/4885LTA4H 3441/4885MCL1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.